about
sameAs
Case-control cohort study of patients' perceptions of disability in mastocytosisMasitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KITMechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cellsThe E3 ubiquitin ligase HOIL-1 induces the polyubiquitination and degradation of SOCS6 associated proteinsCell-to-cell spread of wild-type herpes simplex virus type 1, but not of syncytial strains, is mediated by the immunoglobulin-like receptors that mediate virion entry, nectin1 (PRR1/HveC/HIgR) and nectin2 (PRR2/HveB)Novel, soluble isoform of the herpes simplex virus (HSV) receptor nectin1 (or PRR1-HIgR-HveC) modulates positively and negatively susceptibility to HSV infectionDNAM-1 and PVR regulate monocyte migration through endothelial junctionsThe V domain of herpesvirus Ig-like receptor (HIgR) contains a major functional region in herpes simplex virus-1 entry into cells and interacts physically with the viral glycoprotein DKIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on MastocytosisMast cell sarcoma: new cases and literature reviewSuppressor of cytokine signaling 1 interacts with the macrophage colony-stimulating factor receptor and negatively regulates its proliferation signalProminent role of the Ig-like V domain in trans-interactions of nectins. Nectin3 and nectin 4 bind to the predicted C-C'-C"-D beta-strands of the nectin1 V domainSuppressor of cytokine signaling 6 associates with KIT and regulates KIT receptor signalingFES kinase participates in KIT-ligand induced chemotaxisThe human PRR2 gene, related to the human poliovirus receptor gene (PVR), is the true homolog of the murine MPH geneComplementary DNA characterization and chromosomal localization of a human gene related to the poliovirus receptor-encoding geneTyrosine kinase inhibitors induce down-regulation of c-Kit by targeting the ATP pocketHotspot mutations in KIT receptor differentially modulate its allosterically coupled conformational dynamics: impact on activation and drug sensitivityNectin4/PRR4, a new afadin-associated member of the nectin family that trans-interacts with nectin1/PRR1 through V domain interactionMasitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse modelPICK-1: a scaffold protein that interacts with Nectins and JAMs at cell junctions.Phenotypic and genotypic characteristics of mastocytosis according to the age of onset.Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study.Mastocytosis among elderly patients: A multicenter retrospective French study on 53 patients.SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes.Lineage-specific enhancers activate self-renewal genes in macrophages and embryonic stem cellsMasitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.Nectin-3 (CD113) interacts with Nectin-2 (CD112) to promote lymphocyte transendothelial migration.Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.The murine homolog of human Nectin1delta serves as a species nonspecific mediator for entry of human and animal alpha herpesviruses in a pathway independent of a detectable binding to gDMutational Hotspot of TET2, IDH1, IDH2, SRSF2, SF3B1, KRAS, and NRAS from Human Systemic Mastocytosis Are Not Conserved in Canine Mast Cell TumorsA randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.Screening of candidate G-quadruplex ligands for the human c-KIT promotorial region and their effects in multiple in-vitro models.Dual Role of the Tyrosine Kinase Syk in Regulation of Toll-Like Receptor Signaling in Plasmacytoid Dendritic CellsDNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in micePost-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosisMasitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a studyThe c-fms gene complements the mitogenic defect in mast cells derived from mutant W mice but not mi (microphthalmia) mice.ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.
P50
Q21092209-98A78F8C-CD5F-44A2-B1AF-71B86B5CFACAQ21142738-8467A689-D5F4-47F8-A0D0-E1F20E661ED0Q24313261-9E982BF4-7020-4749-B744-78D7EA6845B0Q24321847-C0B057EF-A89D-477B-A5B1-1FA0CE7C88B8Q24524818-573A4E94-D48B-4654-99D6-39548A836337Q24529140-0FD3E2FB-BDEE-4398-8DEF-F705F6FC8439Q24647699-D9D8DF69-EF9E-4312-91A5-5A97AC75F245Q24658082-13A23F71-73BA-4269-BE24-DAC402CB2D15Q26830207-F872CC7D-D2F0-4959-8026-5015AEA504ACQ28071802-A0C3E0F0-83CE-466B-AD25-762614DCB226Q28211775-FA8FAC49-37DF-42DD-8BBC-4869D633B3E7Q28217548-1AB0DF20-CEF4-45C9-8BFE-AEDA12E91897Q28237281-8B239B7F-495B-4FAB-96BE-31840C7B840BQ28271839-9619FA13-1619-469B-89DD-67D2C2A3956DQ28294076-03B55F09-E4BE-41CD-BD71-3BE4CD0467EFQ28300125-DF37D943-C9FB-417A-8FF3-7D20E2E3E5CDQ28486691-D5F36123-5C68-4C2F-8C6E-3CC7C8096238Q28541374-1F4D99BA-C0FC-4C6A-AE88-558040A70386Q28592530-C9D2C935-DE55-4F23-8C5B-0B2641D929F4Q28748653-570113EC-CF7A-4B6C-AEF8-B355DE276AD5Q33289444-DBE308C4-5A40-401F-B9B0-602EE6F679D1Q33327689-7CA14AE1-3B5A-4B41-A3CC-841B02CCB63FQ33406035-4EE014A3-A3D5-4E41-B90D-873B79667108Q33433126-7B3F8E32-8B2A-4D22-833D-44752BE70FE7Q33558793-FBF62083-4DEC-48D2-9724-8D04F40C31C9Q34045921-DEB69C47-BDAD-4EA3-984C-CE15A7931CF3Q34083140-6DFFC16E-07DD-445A-B7AA-8CF43EE77115Q34301521-C1946BB0-9BA4-4A99-B0C6-D27370D811ACQ35015159-70C21F45-7569-444A-8D48-47197F507C13Q35579238-43077B1D-9F5A-4CE1-A17C-191F0176D613Q35700036-0422F4AC-F779-454B-8D01-7E48966EF8E9Q35839839-BEC7514F-F451-43B5-9C5F-1EA08920C37FQ35892017-1B289AAE-DDD2-4A75-8D2A-984A69523181Q35945953-6424704C-FD1C-42BF-A2D8-D6D0247963A5Q36039695-8AFCE33B-A622-4987-9CDC-2F5A306F09C9Q36908743-57BAC00D-D883-4261-B6AC-8C458AE35C52Q37085041-80C16843-2F68-4C63-88C2-4463E665263DQ37270882-E1F941C2-DE23-45C0-B922-FA5D82105CA4Q37438572-8F6244AB-E2E8-4FEE-951C-BB36394CB5C7Q37499442-AE9E8A36-3933-4AD8-9305-6F2B73A8FD7F
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Patrice Dubreuil
@ast
Patrice Dubreuil
@en
Patrice Dubreuil
@es
Patrice Dubreuil
@nl
Patrice Dubreuil
@sl
type
label
Patrice Dubreuil
@ast
Patrice Dubreuil
@en
Patrice Dubreuil
@es
Patrice Dubreuil
@nl
Patrice Dubreuil
@sl
prefLabel
Patrice Dubreuil
@ast
Patrice Dubreuil
@en
Patrice Dubreuil
@es
Patrice Dubreuil
@nl
Patrice Dubreuil
@sl
P106
P21
P31
P496
0000-0003-1155-1150